Arrowstreet Capital’s Adaptimmune Therapeutics ADAP Stock Holding History

Arrowstreet Capital’s Portfolio ADAP Stock Details ADAP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-32,586	Closed	-$48K	–	1323
2022 Q4	$48K	Buy	+32,586	New	+$52.8K	﹤0.01%	1304
2018 Q3	–	Sell	-68,665	Closed	-$815K	–	1065
2018 Q2	$815K	Buy	68,665 +2,100	+3%	+$26.2K	﹤0.01%	846
2018 Q1	$748K	Buy	66,565 +29,977	+82%	+$262K	﹤0.01%	909
2017 Q4	$244K	Buy	+36,588	New	+$283K	﹤0.01%	1153

Other funds holding ADAP

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ECM

Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return

Arrowstreet Capital's ADAP Position: Q1 2023 in Review

Arrowstreet Capital sold out of Adaptimmune Therapeutics (ADAP) in Q1 2023, closing a stake of 32,586 shares — an estimated $48K sold.

Arrowstreet Capital first reported a position in ADAP in Q4 2017 and held it in 4 quarters. The position peaked at $815K in Q2 2018. 65 funds tracked by Wall St. Rank hold ADAP as of Q1 2023.

Arrowstreet Capital reported no remaining Adaptimmune Therapeutics position as of Q1 2023 after selling out during the quarter.
Arrowstreet Capital sold 32,586 Adaptimmune Therapeutics shares in Q1 2023, an estimated $48K.
Arrowstreet Capital first reported a position in Adaptimmune Therapeutics in Q4 2017 and held it in 4 quarters.
Arrowstreet Capital's Adaptimmune Therapeutics position peaked at $815K in Q2 2018.
65 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q1 2023.

Based on Arrowstreet Capital's 13F filing for Q1 2023, filed 15 May 2023.